Science

Biomarker testing in lung cancer: from bench to bedside

Shrinidhi Nathany and Ullas Batra

Jan 11, 2025, 17:09

Biomarker testing in lung cancer: from bench to bedside

Brittney Abernathy, Journal Manager at Frontiers, shared a recent article by Ullas Batra on LinkedIn:

“Biomarker testing in lung cancer: from bench to bedside.

This comprehensive review of oncology reviews by Dr. Ullas Batra and Shrinidhi Nathany highlights the pivotal role of biomarker testing in non-small-cell lung cancer (NSCLC), emphasizing the transition from therapeutic nihilism to enthusiastic optimism in treatment approaches.

The article outlines the evolution of biomarker testing, from traditional single-gene assays to the advent of next-generation sequencing (NGS). It presents a compelling case for the adoption of multigene panel testing using NGS, which offers a more comprehensive and efficient approach to identifying actionable genetic alterations.

We were particularly intrigued by the detailed discussion of various biomarkers such as EGFR, ALK, ROS1, BRAF, MET, KRAS, ERBB2, and emerging targets like NRG fusions. The review not only covers the prevalence and clinical significance of these biomarkers but also explores corresponding targeted therapies and their impact on patient outcomes.

The article’s emphasis on the importance of integrating NGS into routine clinical practice is noteworthy. It underscores how this technology can overcome the limitations of sequential single-gene testing, potentially leading to more precise treatment strategies and improved patient care.

This review serves as an excellent resource for oncologists and researchers, providing a comprehensive overview of the current landscape of biomarker testing in NSCLC and offering insights into future directions in this rapidly evolving field.

What are your thoughts on the challenges and opportunities in implementing widespread NGS testing in clinical oncology practice?”

‘Biomarker testing in lung cancer: from bench to bedside‘

Authors: Ullas Batra and Shrinidhi Nathany

lung cancer